Nasdaq Regulation



Eun Ah ChoiSenior Vice President
U.S. Listing Qualifications & Market Surveillance

May 12, 2022

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on May 10, 2022 The Nasdaq Stock Market LLC (the "Exchange") received from OKYO Pharma Limited (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

American Depositary Shares, each representing 65 ordinary shares, no par value

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

Em Als Chri